A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

Trial Profile

A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms KEYNOTE-051
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Jun 2017 Results (n=66, data cut off: Nov 7, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 14 Mar 2017 Results (n = 40) published in a Merck and Co. media release.
    • 14 Mar 2017 The US FDA has approved KEYTRUDA (pembrolizumab) for the treatment of adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy. The approval was based on this trial and KEYNOTE-081 (CT profile 700257390), according to a Merck and Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top